E-Cig Use
Conditions
Brief summary
Over the last decade, e-cigarettes have become increasingly popular, due to their promotion as a healthy alternative to traditional tobacco cigarettes. However, there are large discrepancies of knowledge in understanding how these e-cigarettes affect the user's health. The overall goal of this study is to evaluate the impact of e-cigarettes usage on user's cardiopulmonary health
Interventions
DRUGTobacco flavored liquid type 1
A commercially available cartridge-based device with tobacco flavored liquid.
DRUGTobacco flavored liquid type 2
A commercially available cartridge-based device with tobacco flavored liquid.
Sponsors
Virginia Commonwealth University
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
BASIC_SCIENCE
Masking
TRIPLE (Subject, Investigator, Outcomes Assessor)
Eligibility
Sex/Gender
ALL
Age
21 Years to No maximum
Healthy volunteers
Yes
Inclusion criteria
E-Cigarette group: * 21 years of age or older * Used e-cigarettes (≥3 times/week for ≥3 months) Non e-cigarette group ● 21 years of age or older
Exclusion criteria
* 20 years old and younger * Use of cigarettes for 15 days or more in the past 60 days * Use of other tobacco products (cigars, hookah, smokeless) weekly or more frequently in the past 60 days * Use of marijuana or any illicit or prescription drugs for non-medical use weekly or more frequently in the past 60 days * Known allergy to propylene glycol or vegetable glycerin * Evidence of cardiovascular, pulmonary, renal, hepatic, metabolic, or cerebral diseases * Disorder or use of medication that affects cardiopulmonary health * Evidence of pregnancy or current nursing
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Change in Peak oxygen consumption (VO2 peak) | Change from baseline to 2 weeks | Participants' peak oxygen consumption (VO2 peak) will be measured using a standardized exercise capacity test performed on a stationary bike. |
| Change in Expiratory Volume | Change from baseline to 2 weeks | Participants expiratory volume will be measured through spirometry using a pulmonary function device. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Change in Skeletal muscle O2 utilization | Change from baseline to 2 weeks | Assessment of skeletal muscle oxygen utilization using near-infrared spectroscopy through the ratio of O2 delivery and O2 extraction |
| Change in Maximal microvascular dilation | Change from baseline to 2 weeks | Participants' microvascular function (maximal dilation) will be measured using local thermal hyperemia. |
Countries
United States
Outcome results
None listed